Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
Maria Dêbiec‐Rychter(Center for Human Genetics), Peter Marynen(Vlaams Instituut voor Biotechnologie)
Cited by 494
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
|Journal of Clinical Oncology|2010|401
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
|Science Translational Medicine|2011|401
Submicroscopic Duplications of the Hydroxysteroid Dehydrogenase HSD17B10 and the E3 Ubiquitin Ligase HUWE1 Are Associated with Mental Retardation
|The American Journal of Human Genetics|2008|220